A novel gene therapy for ischemic heart disease based on engineered external vesicles with high efficiency and low immunogenicity
Ischemic injury is the number one cause of death and disease in the world, including the United States and China, and vascular endothelial growth factor (VEGF) gene therapy holds promise for patients with ischemic injury. However, the high immunogenicity of traditional viral vectors (such as adeno-associated virus AAV) and the low expression efficiency of lipid…